BR112021015092A2 - Proteína de fusão, sistema de rna guia duplo, e, rna guia - Google Patents

Proteína de fusão, sistema de rna guia duplo, e, rna guia

Info

Publication number
BR112021015092A2
BR112021015092A2 BR112021015092A BR112021015092A BR112021015092A2 BR 112021015092 A2 BR112021015092 A2 BR 112021015092A2 BR 112021015092 A BR112021015092 A BR 112021015092A BR 112021015092 A BR112021015092 A BR 112021015092A BR 112021015092 A2 BR112021015092 A2 BR 112021015092A2
Authority
BR
Brazil
Prior art keywords
guide rna
fusion protein
fragment
dual
editing
Prior art date
Application number
BR112021015092A
Other languages
English (en)
Inventor
Chen Jia
Yang Bei
Yang Li
Huang Xingxu
Wang Lijie
Original Assignee
Univ Shanghai Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Shanghai Technology filed Critical Univ Shanghai Technology
Publication of BR112021015092A2 publication Critical patent/BR112021015092A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21111—Aqualysin 1 (3.4.21.111)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22044—Nuclear-inclusion-a endopeptidase (3.4.22.44)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROTEÍNA DE FUSÃO, SISTEMA DE RNA GUIA DUPLO, E, RNA GUIA. São providas proteínas de fusão e moléculas relacionadas úteis para conduzir a edição de base com mutações fora do alvo reduzidas ou sem mutações. A proteína de fusão pode incluir um primeiro fragmento compreendendo uma nucleobase desaminase ou um domínio catalítico da mesma, um segundo fragmento compreendendo um inibidor da nucleobase desaminase e um local de clivagem de protease entre o primeiro fragmento e o segundo fragmento. Também são providos sistemas de edição principal aprimorados, incluindo RNA guia de edição principal com estabilidade aprimorada.
BR112021015092A 2019-02-02 2020-02-03 Proteína de fusão, sistema de rna guia duplo, e, rna guia BR112021015092A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019074577 2019-02-02
PCT/CN2020/074218 WO2020156575A1 (en) 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing

Publications (1)

Publication Number Publication Date
BR112021015092A2 true BR112021015092A2 (pt) 2022-10-11

Family

ID=71841894

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015092A BR112021015092A2 (pt) 2019-02-02 2020-02-03 Proteína de fusão, sistema de rna guia duplo, e, rna guia

Country Status (11)

Country Link
US (3) US11384353B2 (pt)
EP (1) EP3918083A4 (pt)
JP (1) JP2022526695A (pt)
KR (1) KR20210126042A (pt)
CN (4) CN116286802A (pt)
AU (2) AU2020214090B2 (pt)
BR (1) BR112021015092A2 (pt)
CA (1) CA3128283A1 (pt)
IL (1) IL285194A (pt)
SG (1) SG11202108303SA (pt)
WO (1) WO2020156575A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230399641A1 (en) * 2020-11-12 2023-12-14 Shanghaitech University Genomic editing of improved efficiency and accuracy
CN112575014B (zh) * 2020-12-11 2022-04-01 安徽省农业科学院水稻研究所 一种碱基编辑器SpCas9-LjCDAL1及其构建和应用
EP4314308A1 (en) * 2021-04-02 2024-02-07 Shanghaitech University Gene therapy for treating beta-hemoglobinopathies
US20220372497A1 (en) * 2021-05-18 2022-11-24 Shanghaitech University Base Editing Tool And Use Thereof
WO2023088440A1 (en) * 2021-11-18 2023-05-25 Correctsequence Therapeutics Regeneration of surface antigen-negative cells
KR102667508B1 (ko) * 2022-02-08 2024-06-11 주식회사 툴젠 프라임 에디팅 시스템을 이용한 게놈 편집의 과정에서 발생 가능한 오프 타겟을 예측하는 방법
WO2024012435A1 (en) 2022-07-11 2024-01-18 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hereditary angioedema
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
WO2024088401A1 (en) * 2022-10-28 2024-05-02 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
WO2024095245A2 (en) 2022-11-04 2024-05-10 LifeEDIT Therapeutics, Inc. Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024109745A1 (en) * 2022-11-21 2024-05-30 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hbv infection
WO2024112957A1 (en) * 2022-11-23 2024-05-30 Amber Bio Inc. Gene-modifying endonucleases
CN117092084B (zh) * 2023-10-20 2024-01-12 浙江迪福润丝生物科技有限公司 Wnv蛋白酶抑制剂的筛选方法和抑制效果评价方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6445314A (en) * 1987-04-16 1989-02-17 Res Corp Technologies Inc Antitumoral
US8288094B2 (en) * 2008-04-09 2012-10-16 Institut Pasteur APOBEC3 mediated DNA editing
US20150166982A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
CN105886498A (zh) * 2015-05-13 2016-08-24 沈志荣 CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA
EP4269577A3 (en) * 2015-10-23 2024-01-17 President and Fellows of Harvard College Nucleobase editors and uses thereof
WO2018052247A1 (ko) * 2016-09-13 2018-03-22 주식회사 툴젠 시토신 디아미나제에 의한 dna에서의 염기 교정 확인 방법
US11192929B2 (en) * 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
CN108342387B (zh) * 2017-01-24 2021-09-24 谭旭 Pcsk9抑制剂类降血脂药的递送系统和生物制剂
CA3062595A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
US20200140842A1 (en) * 2017-05-25 2020-05-07 The General Hospital Corporation Bipartite base editor (bbe) architectures and type-ii-c-cas9 zinc finger editing
CN109136272A (zh) * 2017-06-15 2019-01-04 中山大学 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其在人生殖系中的应用
CN109021111B (zh) * 2018-02-23 2021-12-07 上海科技大学 一种基因碱基编辑器

Also Published As

Publication number Publication date
US11384353B2 (en) 2022-07-12
CN116286802A (zh) 2023-06-23
AU2022287550A1 (en) 2023-02-02
SG11202108303SA (en) 2021-08-30
US20240026342A1 (en) 2024-01-25
CA3128283A1 (en) 2020-08-06
AU2020214090A1 (en) 2021-09-16
US20230094769A1 (en) 2023-03-30
EP3918083A1 (en) 2021-12-08
CN116355966A (zh) 2023-06-30
EP3918083A4 (en) 2023-03-29
CN116656676A (zh) 2023-08-29
JP2022526695A (ja) 2022-05-26
CN113661248B (zh) 2022-09-16
US11840685B2 (en) 2023-12-12
AU2020214090B2 (en) 2022-09-15
KR20210126042A (ko) 2021-10-19
CN113661248A (zh) 2021-11-16
WO2020156575A1 (en) 2020-08-06
IL285194A (en) 2021-09-30
US20220064626A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
BR112021015092A2 (pt) Proteína de fusão, sistema de rna guia duplo, e, rna guia
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
BR112021012665A2 (pt) Polipeptídeos úteis para edição de genes e métodos de uso
BR112015012375A2 (pt) modificação e regulação de genoma à base de crispr
AR062916A1 (es) Un sistema basado en facs y en proteinas informadoras para el desarrollo de alto rendimiento de proteinas terapeuticas
BR112012011529A2 (pt) sistema de laser, e, método para escanear um feixe de laser
ECSP088262A (es) Proteínas de fusión de albúmina
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
HUP0202442A2 (hu) Több citokinből és ellenanyagból álló komplexek
BR112017017233A2 (pt) métodos e sistemas para enviar ordens
CY1115634T1 (el) Μεσα ανταγωνιστικης επιλεκτικης συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
DE602005022056D1 (de) Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind
BRPI0515760A (pt) proteìnas de fusão
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DE602006007037D1 (de) Pyrrolotriazin-kinasehemmer
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
DK1847611T3 (da) Rhamnose-inducerbart ekspressionssystem
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
Al-Furoukh et al. NOA1, a novel ClpXP substrate, takes an unexpected nuclear detour prior to mitochondrial import
ATE454454T1 (de) Multifunktionelle und multivalente angiogenese- inhibitoren
BR112022022937A2 (pt) Proteínas de fusão estabilizadas de proteína de pico de coronavírus
ATE326984T1 (de) Verfahren zur verbindung von molekularen substanzen
BR112022004920A2 (pt) Sistemas e métodos para expressão de proteínas
MX2023004335A (es) Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas.